Brian Kidd - Stereotaxis RD Devel

Stereotaxis Management Efficiency

The company has return on total asset (ROA) of (0.2935) % which means that it has lost $0.2935 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0646) %, meaning that it created substantial loss on money invested by shareholders. Stereotaxis' management efficiency ratios could be used to measure how well Stereotaxis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to gain to -0.72 in 2024. At this time, Stereotaxis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 38.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 4.7 M in 2024.

Similar Executives

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri. Stereotaxis operates under Medical Instruments Supplies classification in the United States and is traded on AMEX Exchange. It employs 130 people. Stereotaxis (STXS) is traded on NYSE MKT Exchange in USA. It is located in 710 North Tucker Boulevard, Saint Louis, MO, United States, 63101 and employs 122 people. Stereotaxis is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Stereotaxis Leadership Team

Stereotaxis Stock Performance Indicators

Additional Tools for Stereotaxis Stock Analysis